Transaction details
Timothy Robert Henrichs, who serves as Chief Financial Officer of Neuraxis, INC (DE:NRXS), disclosed the acquisition of 7,593 shares of common stock on April 1, 2026, via a Form 4 filed with the Securities and Exchange Commission. The purchase price was $1.96 per share, resulting in a total transaction value of $14,882.
Market context
The timing of Henrichs' purchase coincides with a period in which NRXS trades well above his purchase price. As of the most recent data cited, the stock was trading at $7.25, marking a substantial increase from the $1.96 paid on April 1. Over the trailing 12 months the shares have returned 272 percent, while the six-month return stands at 128 percent, according to the InvestingPro figures referenced in the filing summary. Analysts maintain positive price targets in a range from $9 to $13, though InvestingPro's Fair Value work indicates the stock appears slightly overvalued at current levels.
Company results highlighted
Separation from the share transaction, Neuraxis reported financial results for the fourth quarter of 2025 that show mixed signals. Revenue for the quarter rose 27 percent to $968,000. Despite that top-line expansion, the company recorded a net loss of $1.7 million for the quarter, wider than the $1.5 million loss reported in the same period a year earlier. Management also reported a decline in gross margin of 100 basis points, which the company attributed to inventory complications and the launch of a lower-margin product.
Investor and analyst reactions
The combination of accelerating revenue and deteriorating profitability has drawn attention from market participants. While some analysts maintain a bullish stance as reflected in the range of price targets, others have flagged the margin deterioration and increased net loss as issues that warrant monitoring. The financial results and the insider purchase together provide investors with data points to weigh when assessing the company's near-term operating trajectory.
Summary assessment
Henrichs' disclosed purchase is a clear insider transaction recorded at an acquisition price of $1.96 per share for a total of $14,882. The stock's subsequent performance, revenue growth, and the widening loss create a mixed picture: stronger top-line momentum on one hand and profitability and margin pressures on the other. Analysts' price targets remain above the current trading price but InvestingPro's Fair Value assessment flags a potential overvaluation.
Key points
- Neuraxis CFO Timothy Robert Henrichs bought 7,593 shares on April 1, 2026, at $1.96 per share, totaling $14,882.
- NRXS has appreciated to $7.25 in recent trading, delivering a 272% one-year return and a 128% six-month return per InvestingPro data.
- Neuraxis reported 27% revenue growth to $968,000 in Q4 2025 but recorded a larger net loss of $1.7 million and a 100 basis point decline in gross margin.
Risks and uncertainties
- Profitability pressure: The company reported a wider net loss year-over-year, which may complicate near-term financial planning and investor sentiment - this impacts equity investors and credit providers.
- Margin compression: A reported 100 basis point decline in gross margin tied to inventory issues and a lower-margin product introduces uncertainty around future margins and unit economics - this affects margins-sensitive sectors and investor valuation models.
- Valuation concerns: InvestingPro's Fair Value analysis suggests the stock may be slightly overvalued relative to analyst targets, creating potential downside risk for market participants relying on valuation metrics.
Investors should note that the details above are drawn from the Form 4 filing and Neuraxis' reported quarterly results. The available information outlines recent insider activity alongside recent operating performance but does not forecast future outcomes.